 |
 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 November 1995 | Volume 123 Issue 9 | Pages 656-664
Objective: To reassess the natural history of polycythemia vera and to obtain reliable estimates of both incidence of thrombosis and survival for use in defining the sample size for therapeutic clinical trials.
Study Design: Retrospective cohort study of patients with polycythemia who had been followed for 20 years.
Setting: 11 Italian hematology institutions.
Patients: 1213 patients with polycythemia vera, which was diagnosed according to criteria established by the Polycythemia Vera Study Group and commonly used in clinical practice.
Main Outcome Measures: All-cause mortality, venous and arterial thrombosis, and hematologic and nonhematologic neoplastic disease. Myocardial infarction and stroke were classified as major thrombotic events, and venous and peripheral arterial thrombosis were considered minor thrombotic events. The number of patients who died and the number of those who had major thrombotic events (combined end point) were used as a comprehensive measure of the benefit-risk ratio associated with the use of myelosuppressive agents.
Results: 634 fatal and nonfatal arterial and venous thromboses were recorded in 485 patients (41%); 36% of these episodes occurred during follow-up in 230 patients (19%), and 64% occurred either at presentation or before diagnosis. Thrombotic events occurred more frequently in the 2 years preceding diagnosis, suggesting a causal relation between the latent myeloproliferative disorder and the vascular event. The incidence of thrombosis during follow-up was 3.4%/y; older patients or those with a history of thrombosis had a higher risk for thrombosis. Overall mortality was 2.9/100 patients per year; thrombotic events and hematologic or nonhematologic cancers had similar effects on mortality. Patients receiving chemotherapy died three to four times more frequently than those not receiving chemotherapy. The increased risk for cancer in patients receiving myelosuppressive agents was seen approximately 6 years after diagnosis. In addition, the combined end point, computed as the sum of the hardest available events (death, nonfatal myocardial infarction, or stroke), suggests that myelosuppressive agents have an overall unfavorable effect.
Conclusions: Cytoreduction favorably affects the incidence of thrombotic events, but aggressive treatment seems to be associated with increased risk for neoplasm. These results provide a basis for reevaluating the therapeutic strategy in patients with polycythemia vera and for estimating the size of clinical trials aimed at testing new therapeutic approaches.
*For members of the Gruppo Italiano Studio Policitemia, see the Appendix.
ARTICLE
Polycythemia Vera: The Natural History of 1213 Patients Followed for 20 Years
This article has been cited by other articles:
 |
|
 |
|
  F. Santilli, M. Romano, A. Recchiuti, A. Dragani, A. Falco, G. Lessiani, F. Fioritoni, S. Lattanzio, D. Mattoscio, R. De Cristofaro, et al. Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients Blood, August 15, 2008; 112(4): 1085 - 1090. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Vannucchi, E. Antonioli, P. Guglielmelli, A. Pancrazzi, V. Guerini, G. Barosi, M. Ruggeri, G. Specchia, F. Lo-Coco, F. Delaini, et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia Blood, August 1, 2008; 112(3): 844 - 847. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Spivak and R. T. Silver The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal Blood, July 15, 2008; 112(2): 231 - 239. [Full Text] [PDF]
|
|
|
|
|
|
J.-J. Kiladjian, F. Cervantes, F. W. G. Leebeek, C. Marzac, B. Cassinat, S. Chevret, D. Cazals-Hatem, A. Plessier, J.-C. Garcia-Pagan, S. D. Murad, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases Blood, May 15, 2008; 111(10): 4922 - 4929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. De Stefano, T. Za, E. Rossi, A. M. Vannucchi, M. Ruggeri, E. Elli, C. Mico, A. Tieghi, R. R. Cacciola, C. Santoro, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments Haematologica, March 1, 2008; 93(3): 372 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ruggeri, F. Rodeghiero, A. Tosetto, G. Castaman, F. Scognamiglio, G. Finazzi, F. Delaini, C. Mico, A. M. Vannucchi, E. Antonioli, et al. Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey Blood, January 15, 2008; 111(2): 666 - 671. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Antonioli, P. Guglielmelli, G. Poli, C. Bogani, A. Pancrazzi, G. Longo, V. Ponziani, L. Tozzi, L. Pieri, V. Santini, et al. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia Haematologica, January 1, 2008; 93(1): 41 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Vannucchi, E. Antonioli, P. Guglielmelli, A. Rambaldi, G. Barosi, R. Marchioli, R. M. Marfisi, G. Finazzi, V. Guerini, F. Fabris, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia Blood, August 1, 2007; 110(3): 840 - 846. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Landolfi, L. Di Gennaro, T. Barbui, V. De Stefano, G. Finazzi, R. Marfisi, G. Tognoni, R. Marchioli, and for the European Collaboration on Low-Dose Aspirin Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera Blood, March 15, 2007; 109(6): 2446 - 2452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Steensma and R. E. Richard Myeloproliferative disorders ASH Self-Assessment Program, January 1, 2007; 2007(1): 172 - 227. [Full Text] [PDF]
|
|
|
|
|
|
A. I. Schafer Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia Blood, June 1, 2006; 107(11): 4214 - 4222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Marchioli, G. Finazzi, R. Landolfi, J. Kutti, H. Gisslinger, C. Patrono, R. Marilus, A. Villegas, G. Tognoni, and T. Barbui Vascular and Neoplastic Risk in a Large Cohort of Patients With Polycythemia Vera J. Clin. Oncol., April 1, 2005; 23(10): 2224 - 2232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Finazzi, V. Caruso, R. Marchioli, G. Capnist, T. Chisesi, C. Finelli, L. Gugliotta, R. Landolfi, J. Kutti, H. Gisslinger, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study Blood, April 1, 2005; 105(7): 2664 - 2670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Johnson, L. Mureebe, and D. Silver Hypercoagulable States: A Review Vascular and Endovascular Surgery, March 1, 2005; 39(2): 123 - 133. [Abstract] [PDF]
|
|
|
|
 |
|
 D Beckett, C Miller, J R Ferrando, and A K Banerjee Polycythaemia vera presenting as massive splenic infarction and liquefaction Br. J. Radiol., October 1, 2004; 77(922): 876 - 877. [Full Text] [PDF]
|
|
|
|
|
|
V. R. Gordeuk, A. I. Sergueeva, G. Y. Miasnikova, D. Okhotin, Y. Voloshin, P. L. Choyke, J. A. Butman, K. Jedlickova, J. T. Prchal, and L. A. Polyakova Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors Blood, May 15, 2004; 103(10): 3924 - 3932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Daya, R. M. Gowda, W. A. Landis, and I. A. Khan Essential Thrombocythemia-Related Acute ST-Segment Elevation Myocardial Infarction: A Case Report and Literature Review Angiology, May 1, 2004; 55(3): 319 - 323. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Landolfi, R. Marchioli, J. Kutti, H. Gisslinger, G. Tognoni, C. Patrono, T. Barbui, and the European Collaboration on Low-Dose Aspirin in Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera N. Engl. J. Med., January 8, 2004; 350(2): 114 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Deeg, T. A. Gooley, M. E. D. Flowers, G. E. Sale, J. T. Slattery, C. Anasetti, T. R. Chauncey, K. Doney, G. E. Georges, H.-P. Kiem, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis Blood, December 1, 2003; 102(12): 3912 - 3918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ruggeri, A. Tosetto, M. Frezzato, and F. Rodeghiero The Rate of Progression to Polycythemia Vera or Essential Thrombocythemia in Patients with Erythrocytosis or Thrombocytosis Ann Intern Med, September 16, 2003; 139(6): 470 - 475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R Deitcher and M. P. Gomes Hypercoagulable state testing and malignancy screening following venous thromboembolic events Vascular Medicine, February 1, 2003; 8(1): 33 - 46. [Abstract] [PDF]
|
|
|
|
 |
|
 A Tzankov, J Krugmann, and G Mikuz Glottis oedema and interstitial pulmonary disease as a result of extramedullary haemopoiesis in polycythaemia vera rubra causing asphyctic death J. Clin. Pathol., January 1, 2003; 56(1): 79 - 79. [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Spivak, G. Barosi, G. Tognoni, T. Barbui, G. Finazzi, R. Marchioli, and M. Marchetti Chronic Myeloproliferative Disorders Hematology, January 1, 2003; 2003(1): 200 - 224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Spivak Polycythemia vera: myths, mechanisms, and management Blood, December 15, 2002; 100(13): 4272 - 4290. [Full Text] [PDF]
|
|
|
|
|
|
R. J. Gumina, D. A. Foley, A. Tefferi, T. W. Rooke, and R. C. Shields Polycythemia Vera: A Case Report and Discussion on Pathogenic Mechanisms of Increased Thrombosis Angiology, September 1, 2002; 53(5): 587 - 591. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Presseizen, Z. Friedman, H. Shapiro, J. Radnay, and M. H. Ellis Phosphatidylserine Expression on the Platelet Membrane of Patients with Myeloproliferative Disorders and its Effect on Platelet-Dependent Thrombin Formation Clinical and Applied Thrombosis/Hemostasis, January 1, 2002; 8(1): 33 - 39. [Abstract] [PDF]
|
|
|
|
 |
|
 H. J. Schmitt, K. Becke, and B. Neidhardt Epidural Anesthesia for Cesarean Delivery in a Patient with Polycythemia Rubra Vera and Preeclampsia Anesth. Analg., June 1, 2001; 92(6): 1535 - 1537. [Full Text] [PDF]
|
|
|
|
|
|
A. Falanga, M. Marchetti, V. Evangelista, A. Vignoli, M. Licini, M. Balicco, S. Manarini, G. Finazzi, C. Cerletti, and T. Barbui Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera Blood, December 15, 2000; 96(13): 4261 - 4266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. L. KASISKE, M. A. VAZQUEZ, W. E. HARMON, R. S. BROWN, G. M. DANOVITCH, R. S. GASTON, D. ROTH, J. D. SCANDLING JR., and G. G. SINGER Recommendations for the Outpatient Surveillance of Renal Transplant Recipients J. Am. Soc. Nephrol., October 1, 2000; 11(2007): S1 - S86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Randi, C. Rossi, F. Fabris, and A. Girolami State-of-the-Art-Review : Essential Thrombocythemia in Young Adults: Major Thrombotic Complications and Complications During Pregnancy A Follow-up Study in 68 Patients Clinical and Applied Thrombosis/Hemostasis, January 1, 2000; 6(1): 31 - 35. [Abstract] [PDF]
|
|
|
|
|
|
T. C. Pearson, M. Messinezy, N. Westwood, A. R. Green, A. J. Bench, A. R. Green, B. J.P. Huntly, E. P. Nacheva, T. Barbui, and G. Finazzi A Polycythemia Vera Update: Diagnosis, Pathobiology, and Treatment Hematology, January 1, 2000; 2000(1): 51 - 68. [Abstract] [Full Text] [PDF]
|
|
Article
